Edwards Lifesciences Q3 Net Income Plunges Post-Divestiture

TL;DR

**EW's Q3 net income looks terrible on paper, but it's mostly due to last year's asset sale; watch those rising litigation costs and impairment charges, they're the real red flags.**

AI Summary

Edwards Lifesciences Corp (EW) reported net sales of $1,553.1 million for the three months ended September 30, 2025, an increase from $1,354.4 million in the prior year period. However, net income attributable to Edwards Lifesciences Corporation significantly decreased to $291.1 million for the quarter, down from $3,070.8 million in Q3 2024, primarily due to the gain on sale of the Critical Care product group in the prior year. For the nine months ended September 30, 2025, net income attributable to EW was $982.3 million, a substantial drop from $3,789.0 million in the same period of 2024, also impacted by the Critical Care divestiture. Operating income from continuing operations for the quarter was $307.1 million, a decrease from $350.6 million in Q3 2024, driven by increased selling, general, and administrative expenses of $514.6 million and certain litigation expenses of $90.4 million. The company also incurred $40.0 million in intangible assets impairment charges during the quarter. Cash and cash equivalents decreased to $2,685.6 million as of September 30, 2025, from $3,045.2 million at December 31, 2024, partly due to $852.8 million in treasury stock purchases. The company completed the purchase of remaining noncontrolling interest in a subsidiary for $233.7 million, eliminating noncontrolling interest from its balance sheet.

Why It Matters

Edwards Lifesciences' significant drop in net income, primarily due to the absence of the Critical Care product group sale from the prior year, masks underlying operational challenges. Increased litigation expenses of $90.4 million and intangible asset impairment charges of $40.0 million signal potential headwinds in its core structural heart business, which is crucial for investors. For employees, the strategic shift away from non-core businesses could mean a sharper focus on implantable medical innovations, but also potential restructuring. Customers might see more concentrated R&D efforts in structural heart, potentially leading to advanced products. Competitively, while the divestiture streamlines operations, the increased operating expenses and impairment charges suggest a tougher market or internal execution issues that could impact its standing against rivals like Medtronic or Abbott.

Risk Assessment

Risk Level: medium — The risk level is medium due to a significant increase in 'Certain litigation expenses' to $90.4 million for the three months ended September 30, 2025, up from $10.8 million in the prior year, and 'Intangible assets impairment charges' of $40.0 million, which were zero in the prior year. These substantial increases in non-recurring expenses indicate potential legal and asset valuation challenges.

Analyst Insight

Investors should scrutinize the details of the increased litigation expenses and intangible asset impairment charges, as these could signal deeper operational or competitive pressures beyond the one-time impact of the Critical Care divestiture. Consider holding off on new positions until more clarity emerges on these specific risks and their potential long-term impact on profitability and future growth in the core structural heart business.

Financial Highlights

revenue

$1,553.1M

total Assets

$13,272.2M

total Debt

$598.2M

net Income

$291.1M

gross Margin

77.8%

cash Position

$2,685.6M

revenue Growth

+14.7%

Revenue Breakdown

Key Numbers

• $1,553.1M — Net sales (Q3 2025) (Increased from $1,354.4M in Q3 2024)
• $291.1M — Net income attributable to EW (Q3 2025) (Decreased significantly from $3,070.8M in Q3 2024 due to prior year's asset sale)
• $90.4M — Certain litigation expenses (Q3 2025) (Increased from $10.8M in Q3 2024)
• $40.0M — Intangible assets impairment charges (Q3 2025) (New charge, zero in Q3 2024)
• $852.8M — Purchases of treasury stock (9 months ended Sep 30, 2025) (Contributed to decrease in cash and cash equivalents)
• $233.7M — Purchase of remaining noncontrolling interest (9 months ended Sep 30, 2025) (Eliminated noncontrolling interest)
• $2,685.6M — Cash and cash equivalents (Sep 30, 2025) (Decreased from $3,045.2M at Dec 31, 2024)
• $514.6M — Selling, general, and administrative expenses (Q3 2025) (Increased from $421.4M in Q3 2024)

Key Players & Entities

• Edwards Lifesciences Corp (company) — registrant
• Critical Care product group (company) — discontinued operations
• U.S. Securities and Exchange Commission (regulator) — filing oversight
• FASB (regulator) — accounting standard setter
• Medtronic (company) — competitor
• Abbott (company) — competitor

FAQ

Risk Factors

• Litigation Expenses [medium — legal]: The company incurred $90.4 million in certain litigation expenses in Q3 2025, a significant increase from $10.8 million in the prior year period. This highlights ongoing legal challenges that can materially impact financial results.
• Intangible Asset Impairment [medium — operational]: Edwards Lifesciences recorded $40.0 million in intangible asset impairment charges during Q3 2025. This indicates a potential overvaluation or reduced future economic benefit from certain acquired intangible assets.
• Treasury Stock Purchases [low — financial]: The company spent $852.8 million on treasury stock purchases in the nine months ended September 30, 2025. While intended to return value to shareholders, significant buybacks can reduce liquidity and cash available for other strategic initiatives.
• Noncontrolling Interest Acquisition [low — financial]: Edwards Lifesciences acquired the remaining noncontrolling interest for $233.7 million in the nine months ended September 30, 2025. This transaction eliminates noncontrolling interest but reduces cash reserves.

Industry Context

Edwards Lifesciences operates in the highly specialized medical device industry, focusing on structural heart disease and critical care monitoring. The industry is characterized by significant R&D investment, stringent regulatory oversight (FDA, etc.), and a competitive landscape with established players and emerging innovators. Trends include the shift towards minimally invasive procedures, technological advancements in device design, and increasing demand driven by an aging global population.

Regulatory Implications

As a medical device manufacturer, Edwards Lifesciences is subject to extensive regulatory scrutiny from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance is critical. Any regulatory non-compliance, product recalls, or delays in approvals can lead to significant financial penalties, reputational damage, and disruptions to sales, impacting future revenue and profitability.

What Investors Should Do

1. Monitor litigation and impairment charges.
2. Analyze SG&A expense growth.
3. Evaluate cash flow generation and deployment.
4. Scrutinize the impact of discontinued operations.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net sales of $1,553.1M and net income of $291.1M, with significant increases in SG&A and litigation expenses.
• 2025-09-30: Balance Sheet Date — Cash and cash equivalents stood at $2,685.6M, down from year-end 2024, reflecting significant treasury stock purchases and noncontrolling interest acquisition.
• 2024-09-30: End of Q3 2024 — Prior year period included a significant gain on sale of the Critical Care product group, impacting year-over-year net income comparisons.

Glossary

Noncontrolling interest

The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership interest of outside shareholders in the consolidated financial statements. (Edwards Lifesciences eliminated this by purchasing the remaining interest, simplifying its balance sheet but reducing cash.)

Treasury stock

Shares of a company's own stock that have been repurchased by the company. These shares are no longer outstanding and do not have voting rights or pay dividends. (Significant purchases of treasury stock ($852.8M in 9 months) reduced the company's cash position.)

Intangible assets impairment charges

A charge taken when the carrying value of an intangible asset on the balance sheet is determined to be higher than its recoverable amount, indicating a loss in value. (A $40.0M charge in Q3 2025 suggests a re-evaluation of the value of certain acquired intangible assets.)

Discontinued operations

A component of a company's business that has been disposed of or is classified as held for sale. Its results are reported separately from continuing operations. (The company reports current and non-current assets and liabilities related to discontinued operations, notably the Critical Care product group divestiture.)

Year-Over-Year Comparison

Compared to the prior year period, Edwards Lifesciences reported a notable increase in net sales for Q3 2025, rising by 14.7% to $1,553.1 million. However, net income attributable to the company saw a dramatic decrease, largely due to the absence of a significant gain on sale of the Critical Care product group in the prior year. Operating income from continuing operations declined due to higher selling, general, and administrative expenses, which increased by $93.2 million, and a substantial rise in litigation expenses from $10.8 million to $90.4 million. The company also incurred new intangible asset impairment charges of $40.0 million, which were not present in the prior year.

Key Financial Figures

• $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange

Filing Documents

• ew-20250930.htm (10-Q) — 2093KB
• ex-101encoreagreement.htm (EX-10.1) — 38KB
• ex-31110xqq32025.htm (EX-31.1) — 11KB
• ex-31210xqq32025.htm (EX-31.2) — 11KB
• ex-3210xqq32025.htm (EX-32) — 6KB
• ew-20250930_g1.jpg (GRAPHIC) — 56KB
• ew-20250930_g10.jpg (GRAPHIC) — 25KB
• ew-20250930_g11.jpg (GRAPHIC) — 24KB
• ew-20250930_g2.jpg (GRAPHIC) — 47KB
• ew-20250930_g3.jpg (GRAPHIC) — 73KB
• ew-20250930_g4.jpg (GRAPHIC) — 74KB
• ew-20250930_g5.jpg (GRAPHIC) — 70KB
• ew-20250930_g6.jpg (GRAPHIC) — 78KB
• ew-20250930_g7.jpg (GRAPHIC) — 79KB
• ew-20250930_g8.jpg (GRAPHIC) — 76KB
• ew-20250930_g9.jpg (GRAPHIC) — 24KB
• image.jpg (GRAPHIC) — 11KB
• 0001099800-25-000062.txt ( ) — 14265KB
• ew-20250930.xsd (EX-101.SCH) — 64KB
• ew-20250930_cal.xml (EX-101.CAL) — 148KB
• ew-20250930_def.xml (EX-101.DEF) — 380KB
• ew-20250930_lab.xml (EX-101.LAB) — 919KB
• ew-20250930_pre.xml (EX-101.PRE) — 665KB
• ew-20250930_htm.xml (XML) — 2564KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Consolidated Condensed Balance Sheets 1 Consolidated Condensed Statements of Operations 2 Consolidated Condensed Statements of Comprehensive Income 3 Consolidated Condensed Statements of Cash Flows 4 Consolidated Condensed Statements of Stockholders' Equity 5 Notes to Consolidated Condensed Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 4.

Controls and Procedures

Controls and Procedures 45 Item 5. O ther Information 4 6 Part II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46 Item 5. Other Information 46 Item 6. Exhibits 47

Signatures

Signatures 48 Table of C o n t e n t s NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act" and together with the Securities Act, the "Acts"). We intend the forward-looking statements contained in this report to be covered by the safe harbor provisions of such Acts. Statements other than statements of historical or current fact in this report or referred to or incorporated by reference into this report are "forward-looking statements" for purposes of these safe harbor provisions. These statements can sometimes be identified by the use of the forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "pro forma," "forecast," "intend," "guidance," "optimistic," "aspire," "confident," or other forms of these words or similar words or expressions or the negatives thereof. Statements regarding past performance, efforts, or results about which inferences or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results; these statements can be identified by the use of words such as "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," "early feedback," or other forms of these words or similar words or expressions or the negatives thereof. These forward-looking statements are subject to substantial risks and uncertainties that could cause our results or future business, financial condition, results of operations or performance to differ materially from our historical results or experiences or those expressed or implied in any forward-looking statements contained in this report. These risks and uncertainties include, but are not limited to: our abil

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements EDWARDS LIFESCIENCES CORPORATION CONSOLIDATED CONDENSED BALANCE SHEETS (in millions, except par value; unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets Cash and cash equivalents $ 2,685.6 $ 3,045.2 Short-term investments (Note 5) 1,156.4 930.7 Accounts receivable, net of allowances of $ 12.6 and $ 11.6 , respectively 693.3 609.1 Other receivables 199.5 118.3 Inventories (Note 2) 1,140.9 1,086.7 Prepaid expenses 125.2 121.0 Other current assets 323.4 347.6 Current assets of discontinued operations (Note 4) 34.6 26.8 Total current assets 6,358.9 6,285.4 Long-term investments (Note 5) 274.7 307.9 Property, plant, and equipment, net 1,743.3 1,686.0 Operating lease right-of-use assets 96.5 98.2 Goodwill 1,768.5 1,776.7 Other intangible assets, net 1,130.8 1,176.6 Deferred income taxes 1,099.9 992.1 Other assets (Note 2) 784.8 721.6 Non-current assets of discontinued operations (Note 4) 14.8 10.8 Total assets $ 13,272.2 $ 13,055.3 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 165.0 $ 197.4 Accrued and other liabilities (Note 2) 1,393.9 1,282.4 Operating lease liabilities 26.8 23.4 Current liabilities of discontinued operations (Note 4) 2.3 2.0 Total current liabilities 1,588.0 1,505.2 Long-term debt 598.2 597.7 Operating lease liabilities 75.3 78.9 Uncertain tax positions 442.9 384.6 Other liabilities 362.6 426.0 Non-current liabilities of discontinued operations (Note 4) 0.2 — Total liabilities 3,067.2 2,992.4 Commitments and contingencies (Note 11) Stockholders' equity Preferred stock, $ 0.01 par value, authorized 50.0 shares, no shares outstanding — — Common stock, $ 1.00 par value, 1,050.0 shares authorized, 658.2 and 654.8 shares issued, and 580.7 and 588.6 shares outstanding, respectively 658.2 654.8 Additional paid-in capital 2,697.4 2,613.4 Retained earnings 14,149.3 13,167.0 Accumulated other comprehensive loss (Note 12) ( 2

View Full Filing

View this 10-Q filing on SEC EDGAR